Status:
RECRUITING
Effect of Supplementation With Creatine on the Recovery of Ischemic Stroke
Lead Sponsor:
Fundació d'investigació Sanitària de les Illes Balears
Collaborating Sponsors:
Comunidad Autónoma de las Islas Baleares (Dirección General de Investigación en Salud, Formación y Acreditación)
Conditions:
Stroke, Ischemic
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Stroke is a leading cause of disability and the second leading cause of death worldwide. Most strokes are ischemic, caused by acute arterial occlusion. Post-stroke treatment focuses on secondary preve...
Detailed Description
Stroke is one of the most impactful health conditions worldwide, currently being the leading cause of disability and the second leading cause of death globally. Approximately 85-90% of strokes are isc...
Eligibility Criteria
Inclusion
- Age between 18 and 80 years
- Recent diagnosis of ischemic stroke (from 24 hours to 5 days) .
- Neurological deficit due to the stroke that affects mobility (paresis and/or ataxia) and requires motor rehabilitation.
- Ability to understand and sign the informed consent form, or failing that, have sufficient support to carry out the correct follow-up of the study.
Exclusion
- Moderate-severe disability prior to stroke, defined by an mRS\>2.
- Unstable or severe clinical situation that prevents active rehabilitation.
- Neurological deficit due to stroke that prevents walking without help from another person. The use of support with a cane, crutch or walker is permitted.
- Moderate or severe dysphagia that makes therapeutic adherence difficult.
- Use of creatine supplements in the last 3 months, or use of anabolic products in the last 3 months.
- Severe kidney disease (GFR \<30ml/min/1.73 m2).
- Musculoskeletal pathology that prevents assessment of muscle strength. For example: fractures, severe osteoarthritis, ligament tears or tendinopathies.
- History of allergic reactions to creatine.
- Pregnancy or breastfeeding.
- Simultaneous participation in another clinical trial.
Key Trial Info
Start Date :
September 27 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT06576466
Start Date
September 27 2024
End Date
July 1 2027
Last Update
July 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IdISBa
Palma de Mallorca, Balearic Islands, Spain, 07120